Immugen^®

Achieving Quiescence™ - This was abandoned in 2002 for lack of use.

Antaggra™ was challenged by Elan Pharmceuticals, Inc., because of its registered mark, Antegren, which was renamed Tysabri for the treatment of multiple sclerosis.  According to the USPTO, the mark, Antegren, is now dead. The tradmark Antaggra could now be used as the name for the lead immunomodulatory drug for the treatment of a variety of diseases including HIV, atherosclerosis, etc.  Such drugs depend on signaling within the immune system which leads to the aggregation of immune cells. Originally it was created for the use of an alkyl resorcinol, IMG-510, which inhibited platelet aggregation and blocked  thromboxane synthase in platelets which is inhibitory of platelet activation.

Virarest™